玻璃体内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的临床研究  

Clinical Study of Intravitreai Compaq Sipp Injection in Patients with Macular Edema Induced by Rranch Retinal Vein Occlusion

作　　者：范金连 曾琦[1] 段国平[1] 

机构地区：[1]湖南师范大学第一附属医院暨湖南省人民医院眼科,湖南长沙410005

出　　处：《医学临床研究》2016年第1期83-85,共3页Journal of Clinical Research

摘　　要：【目的】初步评价玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞（BRV0）继发黄斑水肿（ME）的疗效及安全性。【方法】对2014年8月至2015年2月就诊于本院眼科已确诊为BRVO继发ME的患者21例（21眼）的临床资料进行回顾性分析，对患眼均给予玻璃体腔内注射康柏西普，观察术前和术后1d、1周、1个月、3个月时患者的最佳矫正视力，光学相干断层扫描测定黄斑中心区视网膜厚度的变化。【结果】在21眼中有19眼视力提高，2眼视力不变。治疗前的LogMRA视力为0．55±0．74，治疗后1周、1个月、3个月时分别为：0．57±0．70、0．61±0．63、0．62±0．58，其与治疗前相比差异均具有显著性（P〈0．05）。黄斑中心凹平均厚度治疗前为（404．25±62．76）μm，治疗后1周、1个月、3个月时分别为（354．25±64．12）μm、（221．75±37．30）μm、（195．30±24．70）μm，治疗后明显改善，与治疗前相比差异具有显著性（P〈0．05）。未发现与药物相关的眼部并发症及全身的不良反应。【结论】玻璃体内注射康柏西普治疗BRVO继发ME患者中短期内可提高视力、减轻ME，但长期疗效仍需进一步观察。[Objective]To evaluate the efficacy and safety of intravitreal compaq sipp injection in patients with macular edema （ME） induced by branch retinal vein occlusion （BRVO）. [Methods]21 patients （21 eyes） with macular edema in patient with branch retinal vein occlusion were diagnosed in our hospital from 2014 August to 2015 Februry. Patients were given compaq sipp injection in vitreous cavity. Best corrected visual acuity （BCVA） was observed at 1 day, 1 week, 1 month, and 3 months after treatment and compared with before treatments. Optical coherence tomography was used to measure the change in macular retinal thickness. [Results]Of the 21 eyes, 19 cases showed improvement in visual acuity and 2 showed no change. LogMAR vision before treatment was 0.55±0.74, and 1 day, 1 week, 1 month, and 3 months after treatment it was 0.57±0.70, 0.61±0.63, and 0.64±0.58, respectively. When compared to before treatment, the differences were statistically significant （ P 〈0.05）. The central macular thickness before treatment was 404.25±62.76μm, and 1 day,1 week,1 months,3 months after treatment it was 354.25±64.12,221.75±37.30, and 195.30±24.70, respectively. Thicknesses after treatment were all lower than before treatment （all P 〈0.05）. Conclusion]Intravitreal injection of compaq sipp for patients with macular edema secondary to branch retinal vein occlusion can improve the visual acuity and releive macular edema in the short-term, but the long-term efficacy remains to be seen. No adverse drug related ocular or systemic complications occurred in our study.

关 键 词：玻璃体 注射 病灶内 血管生成抑制剂/治疗应用 抗体 单克隆/治疗应用 视网膜静脉闭塞/并发症 黄斑水肿/病因学 

分 类 号：R774.5[医药卫生—眼科]